ISSN 0482-5004 printed version
Scope and policy
The Brazilian Journal of Rheumatology (BJR) is owned and published by the Sociedade Brasileira de Reumatologia and publishes manuscripts focusing on subjects related to the rheumatology field, after analysis by the Editorial Board and peer-review. The BJR is published bimonthly and is indexed on Web of Science , PUBMED/MEDLINE, Lilacs (Literatura Latino-Americana e do Caribe em Ciências da Saúde), Scopus, index Copernicus and Scielo (Scientific Electronic Library Online) databases. After submitting a manuscript, the author (s) assumes responsibility for the scientific content and declare that the material neither has been published previously nor is being considered for publication elsewhere. The manuscript has to be original and has to be approved by all authors. Accepted manuscripts constitute a property of the BJR. This publication may be shared immediately with attribution, but not for commercial or derivative purposes; that is, it allows unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. Articles accepted for publication become the property of the journal.
Submitted manuscripts will be analyzed only if rigorously compliant with the rules specified below.
Its abbreviated title is Rev. Bras. Reumatol., which should be used in bibliographies, footnotes and bibliographical references and strips.
There are no fees for submission and evaluation of articles.
The Journal adopts iThenticate system for all submitted manuscripts; the top pairing index identifying the files are being evaluated by the editors.
Manuscripts will be evaluated initially by editor-in-chief and / or associate editor, and found to comply with format and scope of the journal, follow for evaluation by at least two reviewers with scientific knowledge in research, national or foreign origin. After the corrections and possible suggestions, the manuscript will receive favorable or unfavorable opinions of reviewers, who subsidize the subsequent re-evaluation and acceptance of recommendation or rejection by the associate editor. Final decisions will be chief editor of the responsibility.
Instructions to authors
Format of the manuscripts
The manuscript can be submitted in Portuguese or English, double spaced, with 2.5 cm margins. Unconventional abbreviations, medical jargon and telegraphic style should not be used in the text. Citation of drugs and pharmaceutical products must be done using pharmacological nomenclature, without any mention to commercial names.
Manuscript*, Title Page*, Cover Letter, and Author Agreement* must be submitted in separate fi les. Tables and Figures should be numbered as cited in the text and sent in separate fi les with corresponding titles and legends. (*required fi les)
The original article should contain: the title page, the abstract page with keywords, introduction, material and methods or patients and methods, results and discussion, acknowledgements, references, tables, figures and figure legends. Original articles should not exceed 5,000 words including references and excluding the title page, abstract, tables and legends. It is allowed up to six figures or tables and 50 references.
Reviews, preferentially systematic, may be submitted to BJR. They should cover deeply any interesting theme for the rheumatologist. They do not present a standard structure, neither introduction or conclusion. Please send abstracts without subdivisions with three to five keywords. Review articles should not exceed 6,000 words including references and excluding the title page, abstract, tables and legends. It is allowed up to five figures or tables and 70 references.
Must have six authors at most. They should include an abstract and keywords, without subdivisions. The text, however, should present the following sections: introduction, which should be concise; case report, containing the description and the evolution of the clinical case, laboratory exams, illustrations and tables (that substitute the sections material and methods and results); and discussion. It should not exceed 1,500 words including references and excluding the title page, abstract, tables and legends. It is allowed up to two figures or tables and 15 references.
It covers a point or a specific detail. It should present an abstract with no more than 250 words and three to five keywords. The text does not include subdivisions, and should not exceed 2,500 words including references and excluding the title page, abstract, tables and legends. It is allowed up to three figures or tables and 25 references.
Rules for applying the appropriate tense in scientific writing:
General rules to obtain a good scientific writing:
Legal and ethical considerations
According to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (International Committee of Medical Journal Editors - February 2006).
Conflict of interest
Public trust in the peer review process and the credibility of published articles depend in part on how well conflict of interest is handled during writing, peer review, and editorial decision making. Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has financial or personal relationships that inappropriately influence (bias) his or her actions (such relationships are also known as dual commitments, competing interests, or competing loyalties). These relationships vary from those with negligible potential to those with great potential to influence judgment, and not all relationships represent true conflict of interest. The potential for conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment. Financial relationships (such as employment, consultancies, stock ownership, honoraria, paid expert testimony) are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, and of science itself. However, conflicts can occur for other reasons, such as personal relationships, academic competition, and intellectual passion.
Patients have a right to privacy, that should not be infringed without informed consent. Identifying information, including patients’ names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifi able be shown the manuscript to be published. Authors should identify Individuals who provide writing assistance and disclose the funding source for this assistance. Identifying details should be omitted if they are not essential.
Complete anonymity is difficult to achieve. However, an informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. When informed consent has been obtained it should be indicated in the published article.
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.
Clinical trials registry
Clinical trials must be registered according to WHO recommendation at www.who.int/ictrp/en/. The defi nition of clinical trial include preliminary trials (phase I): any study with prospective recruiting of subjects to undergo any health-related intervention (drugs, surgical procedures, equipment, behavioral therapies, food regimen, changes in health care) to evaluate the effects on clinical outcomes (any biomedical or health-related parameter, including pharmacokinetics measurements and adverse reactions). The BJR has the right not to publish trials not complying with these and other legal and ethical standards determined by international guidelines.
Financing and support
The authors should also inform if they received financing or support from institutions like CNPq, CAPES, SBR Remaining Funds, Graduated Institutions, Laboratories etc.
Secretaria Editorial RBR
Revista Brasileira de Reumatologia
Submission of manuscripts
To submit a manuscript, please access the site http://ees.elsevier.com/bjr.
[Home] [About the journal] [Editorial board] [Subscriptions]
All the content of the journal, except where otherwise noted, is licensed under a Creative Commons License
Secretaria Editorial RBR
Revista Brasileira de Reumatologia
Av. Brigadeiro Luiz Antonio, 2.466 - conjs. 93-94
01402-000 - São Paulo- SP - Brasil
Tel./fax: +55 11 3289-7165